Aggregate European sales by 10 innovator pharmas fell $10.1 billion (11%) in 2012 compared to 2011, while U.S. sales dropped $6.2 billion (5%). The U.S. falloff was driven by patent expirations for large products at four companies. Three of the big pharmas actually saw double-digit increases in U.S. sales, while only Novo Nordisk A/S (CSE:NVO; NYSE:NVO) saw an uptick in Europe though the gain was modest at about $140 million (4%). The eight companies that break out emerging markets sales saw an aggregate increase of $4.1 billion (6%). Although that helped